Eli Lilly and Company
- Open
- 1168.47
- Day high
- 1171.45
- Day low
- 1147.00
- Prev close
- 1172.86
- Volume
- 2.8M
- Mkt cap
- $1.09T
- P/E (TTM)
- 38.8
- EPS (TTM)
- $29.85
- P/B
- 32.2
- P/S
- 13.7
- Yield
- 0.58%
- Per share
- $6.69
- ▼Insiders net selling -$18.8M over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions accumulating (13F)
Eli Lilly and Company (LLY) is a Healthcare company listed on NYSE. The stock is up 58% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4). Drillr has 12 published research articles covering LLY.
Eli Lilly and Company (LLY) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 13 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
LLY earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $6.54 | $8.38 | +28.1% | $23.0B | +9.8% |
| Apr 30, 2026 | $6.96 | $8.55 | +22.9% | $19.8B | +10.9% |
| Feb 4, 2026 | $7.00 | $7.54 | +7.7% | $19.3B | +7.0% |
| Oct 30, 2025 | $5.62 | $7.02 | +25.0% | $17.6B | +9.8% |
| Aug 7, 2025 | $5.60 | $6.31 | +12.7% | $15.6B | +5.8% |
| May 1, 2025 | $3.26 | $3.34 | +2.5% | $12.7B | +0.5% |
| Feb 6, 2025 | $5.03 | $5.32 | +5.8% | $13.5B | — |
| Oct 30, 2024 | $1.47 | $1.18 | -19.7% | $11.4B | -5.4% |
| Aug 8, 2024 | $2.60 | $3.92 | +50.8% | $11.3B | +13.2% |
| Apr 30, 2024 | $2.46 | $2.58 | +4.9% | $8.8B | -1.9% |
| Feb 6, 2024 | $2.22 | $2.49 | +12.2% | $9.4B | +4.7% |
| Nov 2, 2023 | $-0.08 | $0.10 | +225.0% | $9.5B | +6.1% |
LLY insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Sulzberger Gabrielledirector | Grant | 4 | $1183.16 |
| Aug 18, 2026 | Alvarez Ralphdirector | Grant | 10 | $1183.16 |
| Aug 18, 2026 | Fyrwald J Erikdirector | Grant | 8 | $1183.16 |
| Aug 18, 2026 | LUCIANO JUAN Rdirector | Grant | 13 | $1183.16 |
| Aug 18, 2026 | Jonsson Patrikofficer: EVP & President, LLY Int'l | Sell | 6,500 | $1175.10 |
| Aug 11, 2026 | Zakrowski Donald Aofficer: SVP, Finance, & CAO | Sell | 2,000 | $1185.01 |
| Aug 10, 2026 | Hakim Anatofficer: EVP, GC & Secretary | Sell | 5,000 | $1190.00 |
| Aug 3, 2026 | Seymour Melissaofficer: EVP, Global Quality | Tax | 439 | $1148.84 |
| Aug 3, 2026 | Seymour Melissaofficer: EVP, Global Quality | Option | 981 | — |
| Jul 21, 2026 | Fyrwald J Erikdirector | Grant | 9 | $1146.90 |
| Jul 21, 2026 | Sulzberger Gabrielledirector | Grant | 4 | $1146.90 |
| Jul 21, 2026 | Alvarez Ralphdirector | Grant | 11 | $1146.90 |
| Jul 21, 2026 | LUCIANO JUAN Rdirector | Grant | 14 | $1146.90 |
| Jun 16, 2026 | LUCIANO JUAN Rdirector | Grant | 14 | $1129.35 |
| Jun 16, 2026 | Alvarez Ralphdirector | Grant | 11 | $1129.35 |
Source: LLY SEC Form 4 filings, latest Aug 18, 2026. For informational purposes only — not investment advice.
See the full LLY insider & 13F page →LLY research & analysis
VKTX Falls 25% on Weight-Loss Drug Safety Data, Hits LLY and NVO
Viking Therapeutics dropped 25% on new weight-loss drug safety data. What the GLP-1 cohort spillover means for LLY, NVO, AMGN.
VKTXNVOAMGNLLY, MRK, PFE: 2026 Biotech M&A Patent Cliff Driver
Biotech M&A 2026 on track for best year since 2018. Patent cliffs (Keytruda 2028, Trulicity 2027) drive LLY/MRK/PFE acquisition urgency.
MRKPFEABBVLLY: $2.3B Ajax Buy Hedges Mounjaro Patent Cliff
Eli Lilly's $2.3 billion Ajax Therapeutics acquisition reveals a critical divergence in large-cap pharma M&A strategy that the market has mispriced. While Merck and Pfizer scramble to replace patent cliff revenue with expensive blockbuster acquisitions, Lilly is buying rare-disease optionality from a position of GLP-1 strength. Long LLY versus short MRK/PFE targets 8-12% relative return over six months as earnings reveal the cost of desperate dealmaking.
MRKPFEBMYEli Lilly's Kelonia Acquisition: Does It Unlock Genetic Medicine Upside Beyond GLP-1?
Eli Lilly closes Kelonia Therapeutics acquisition, integrating gene therapies for cancer that extend growth beyond GLP-1 drugs. Shares look undervalued at 55x PE versus gene therapy peers. Long LLY to $1,050 in 12 months, breaks without Phase 1 progress by mid-2027.
Pharma Tariffs: Buy LLY & AMGN, Sell PFE & MRK — Here's Why
Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.
AMGNABBVJNJTrump 100% Pharma Tariffs: PFE and MRK Face $200M Hit While LLY Gains 25%
Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.
PFEMRKTMOLLY Acquires CNTA for $7.8B: Options Traders Pile In as Stock Surges 44%
Options traders swarmed CNTA calls after Eli Lilly confirmed its $7.8B buyout, driving a 44% surge to $39.61 amid closing buzz. The deal slots orexin sleep assets into LLY's obesity powerhouse, backed by $65B 2025 revenue and $80B+ 2026 guide. Bullish: Synergies outweigh premium in a 25x fwd P/E beast.
CNTAPharma Tariffs: LLY and AMGN Win While PFE and MRK Face Margin Squeeze
Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.
AMGNABBVJNJLLY Stock Dips on Foundayo Approval — Is the GLP-1 Oral Drug a NVO Killer?
Eli Lilly's shares fell despite Foundayo (orforglipron) FDA approval due to geopolitical tensions, but the oral GLP-1's no-restrictions profile positions it to challenge Novo's injectable dominance. LLY's stellar growth (45% revenue surge) contrasts Novo's slowdown (-5-13% 2026 guidance), making the dip a potential entry point. Watch initial uptake and competitive filings for share shifts.
NVOLLY FDA Approval: Oral Obesity Pill Foundayo Threatens NVO's Wegovy as Revenue Surges 45%
FDA approval of Lilly's oral obesity pill Foundayo (orforglipron) intensifies rivalry with Novo's Wegovy, with Lilly's superior growth and oral convenience poised to capture needle-averse patients. NVO's guidance cuts highlight vulnerabilities, favoring LLY overweight amid 45% revenue surge vs. NVO's 6%. Key: Q1 2026 uptake and Medicare dynamics.
NVOFTC Insulin Crackdown: CVS Settles — What It Means for LLY, NVO, and WBA
CVS Health's recent settlement with the FTC over insulin pricing marks a pivotal moment in the pharmaceutical landscape. This article analyzes the potential winners and losers among pharmacies and drugmakers as regulatory scrutiny intensifies, highlighting key players like Eli Lilly, Novo Nordisk, and Walgreens Boots Alliance.
CVSWBANVOPharma Tariffs: LLY, TMO, CVS Supply Chain Exposure Ranked by Risk
Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.
PFEMRKTMO
Eli Lilly and Company company profile
Overview
Eli Lilly and Company (NYSE:LLY) is a major American pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company has evolved from a small Indianapolis pharmacy into one of the world's largest pharmaceutical manufacturers, with a particular focus on diabetes care, oncology, immunology, and neuroscience. Lilly went public in 1972 and has established itself as a leader in innovative drug development, with recent breakthrough success in diabetes and obesity treatments that have transformed both the company's financial performance and market position in the healthcare sector.
Business
Eli Lilly operates in the global pharmaceutical industry, discovering, developing, manufacturing, and marketing prescription medications for human use. The company's business spans multiple therapeutic areas with distinct product portfolios. Diabetes and Obesity Care represents Lilly's largest and fastest-growing segment, accounting for approximately 60% of total revenue. The flagship products include Mounjaro (tirzepatide), a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist for type 2 diabetes, and Zepbound (also tirzepatide), the same molecule approved specifically for chronic weight management in obese adults. These medications work by mimicking hormones that regulate blood sugar and slow gastric emptying, leading to improved glycemic control and significant weight loss. The portfolio also includes traditional insulin products like Humalog and Humulin, as well as other diabetes medications like Jardiance and Trulicity. Oncology comprises roughly 25% of revenue, featuring cancer treatments such as Verzenio for breast cancer, Cyramza for various solid tumors, and Jaypirca for blood cancers. These are targeted therapies that work by blocking specific proteins or pathways that cancer cells need to grow and survive. Immunology accounts for approximately 10% of revenue, including Taltz for autoimmune skin and joint conditions, and Olumiant for rheumatoid arthritis. These medications suppress overactive immune responses that cause chronic inflammation. Neuroscience represents about 5% of revenue, featuring treatments like Cymbalta for depression and anxiety, and recently approved Kisunla for early-stage Alzheimer's disease. The Alzheimer's treatment works by removing amyloid plaques from the brain, which are believed to contribute to cognitive decline.
Revenue model
Eli Lilly generates revenue primarily through direct pharmaceutical product sales to wholesalers, pharmacies, hospitals, and healthcare systems globally. The company operates under a traditional pharmaceutical business model where it invests heavily in research and development to create proprietary medications, obtains regulatory approval, and then sells these products at premium prices during patent protection periods. The company's customers include pharmaceutical wholesalers like McKesson and Cardinal Health, retail pharmacy chains, hospital systems, and increasingly, specialty pharmacies that handle complex medications requiring special handling or patient support services. For newer products like Mounjaro and Zepbound, Lilly works directly with specialty pharmacies and offers patient assistance programs to improve access. Revenue growth is driven by several factors. Volume expansion occurs as more patients gain access to treatments through improved insurance coverage and increased physician adoption. Geographic expansion provides growth as Lilly launches products in new international markets. Indication expansion allows the same molecule to treat additional conditions, as seen with tirzepatide's approval for both diabetes and obesity, with potential future approvals for heart failure and sleep apnea. Margin pressures come from multiple sources. Generic competition dramatically reduces revenue when patents expire, as seen with older products like Cymbalta. Pricing pressure from government healthcare systems, insurance companies, and pharmacy benefit managers continuously challenges profitability. Manufacturing scale-up costs are substantial, particularly for complex biologics and newer formulations. Regulatory compliance and quality control requirements add ongoing operational expenses. However, margins benefit from manufacturing scale efficiencies as production volumes increase, and product mix shifts toward newer, higher-margin treatments can improve overall profitability.
Competitive moat
Eli Lilly possesses a moderately strong competitive moat built on several complementary factors, though it faces typical pharmaceutical industry vulnerabilities. The company's primary moat stems from patent protection on key products, particularly the breakthrough tirzepatide molecule used in both Mounjaro and Zepbound. These patents provide exclusive market access for years, allowing premium pricing and market share building before generic competition emerges. Regulatory expertise and clinical development capabilities create significant barriers to entry. Lilly's ability to design, execute, and navigate complex clinical trials through FDA approval processes represents decades of accumulated knowledge and relationships. The company's track record of successful drug approvals provides credibility with regulators and physicians that competitors must work years to establish. Manufacturing complexity serves as another protective factor, especially for biologics and complex formulations. Lilly's substantial investments in specialized manufacturing facilities - over $23 billion since 2020 - create both capacity advantages and technical barriers that competitors cannot easily replicate quickly. However, the moat faces significant challenges. Patent expiration represents the most serious threat, as products inevitably face generic competition that can eliminate 80-90% of revenue within months. Competitive innovation in diabetes and obesity treatments is intense, with companies like Novo Nordisk offering similar GLP-1 therapies, and emerging competitors developing potentially superior treatments. Regulatory risk remains substantial, as clinical trial failures or safety concerns can rapidly destroy years of investment and market position. The sustainability of Lilly's moat depends heavily on continued innovation success and pipeline execution. While the company currently enjoys strong positioning in high-growth therapeutic areas, maintaining leadership requires consistent R&D success in an increasingly competitive and expensive drug development environment.
Risks & safety
Eli Lilly presents a moderate margin of safety profile with strong cash generation but elevated valuation metrics and significant debt levels. • Liquidity and Solvency: Cash position of $3.3 billion provides adequate short-term liquidity, though relatively modest given company size. Debt-to-equity ratio of 2.37 indicates high leverage but manageable given strong cash flows. Operating cash flow of $8.8 billion annually demonstrates strong cash generation capability. • Valuation Concerns: Price-to-earnings ratio of 65.7x reflects extremely high valuation expectations. EV/EBITDA of 47.7x suggests significant premium pricing. Price-to-book ratio of 49.0x indicates substantial intangible asset valuation risk. • Financial Stability: Current ratio of 1.15x shows adequate short-term asset coverage. Free cash flow of $414 million (2024) represents minimal cash generation after capital expenditures, reflecting heavy manufacturing investments. • Other Considerations: Revenue concentration in diabetes/obesity products creates single-point-of-failure risk. Patent expiration timeline creates predictable future revenue cliffs. High R&D spending requirements limit financial flexibility.
Recent development
Over the past few years, Eli Lilly has undergone a dramatic strategic transformation centered around its breakthrough diabetes and obesity treatments. The company's most significant development has been the successful launch and rapid scaling of tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity. This single molecule has become the company's primary growth driver, generating over $13 billion in combined revenue by 2024. Lilly has made unprecedented manufacturing investments, committing over $23 billion since 2020 to build and expand production facilities globally. This includes major expansions in Indiana, North Carolina, Ireland, and Germany, specifically designed to meet the explosive demand for incretin-based therapies. The company achieved its target of 1.5x production capacity increase in the second half of 2024, eliminating supply constraints that had limited growth. The pipeline strategy has evolved to focus heavily on next-generation obesity and diabetes treatments. Lilly is developing orforglipron, an oral GLP-1 medication that could eliminate the need for injections, with obesity submission expected in late 2025. The company has also expanded tirzepatide's potential applications, submitting for heart failure treatment and obstructive sleep apnea, which could significantly broaden the addressable market. In oncology, Lilly has strengthened its position through strategic acquisitions, including Morphic Therapeutics and POINT Biopharma, while advancing its existing portfolio with new approvals for Jaypirca and Verzenio in additional indications. The neuroscience portfolio has been bolstered by the approval of Kisunla for Alzheimer's disease, representing a new treatment approach for this challenging condition. Internationally, the company has accelerated global expansion efforts, particularly in Europe and Asia, where Mounjaro launches are driving significant revenue growth. The strategy emphasizes building market access and reimbursement relationships to support long-term growth in these regions.
LLY company profile · for informational purposes only — not investment advice.
Track LLY with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free